Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Review ArticleReview
Open Access

The Implication of X-Linked Genetic Polymorphisms in Susceptibility and Sexual Dimorphism of Cancer

CHAROULA ACHILLA, THEODOSIOS PAPAVRAMIDIS, LEFTERIS ANGELIS and ANTHOULA CHATZIKYRIAKIDOU
Anticancer Research May 2022, 42 (5) 2261-2276; DOI: https://doi.org/10.21873/anticanres.15706
CHAROULA ACHILLA
1Laboratory of Medical Biology - Genetics, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
THEODOSIOS PAPAVRAMIDIS
2First Propedeutic Department of Surgery, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LEFTERIS ANGELIS
3School of Informatics, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANTHOULA CHATZIKYRIAKIDOU
1Laboratory of Medical Biology - Genetics, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chatzikyra@auth.gr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The X-chromosome is implicated in cancer development through various mechanisms, including X-inactivation defects, loss of heterozygosity, and germline and somatic alterations of X-linked genes. Sex is a key factor which influences cancer susceptibility as many cancer types show sexual dimorphism in their incidence. The aim of this review was to summarize the germline genetic polymorphisms lying on the X-chromosome that have been associated with cancer susceptibility and to evaluate their possible implication in cancer-related sexual dimorphism. PubMed and Web of Science were searched using the terms “X-chromosome”, “polymorphism” and “cancer”. The literature review revealed 39 articles reporting 33 genetic variants in 22 X-linked genes as being associated with cancer risk. Most of these genes interact with each other in a direct or indirect way, as GeneMANIA software revealed, demonstrating the complication of the mechanisms through which they are involved in tumorigenesis. Polymorphisms in eight genes [androgen receptor (AR), fibroblast growth factor 13 (FGF13), forkhead box P3 (FOXP3), L1 cell adhesion molecule (L1CAM), nudix hydrolase 11 (NUDT11), Shroom family member 2 (SHROOM2), transcription elongation factor A-like 7 (TCEAL7) and TIMP metallopeptidase inhibitor 1 (TIMP1)] are reported to have a sex-specific association with cancer susceptibility, which might explain the sexual dimorphism of certain cancer types. All of the above eight mentioned genes, with the exception of L1CAM, exhibit differences in their expression pattern between breast tumor (sex-specific)/thyroid tumor (sex-influenced) vs. normal tissues according to our analysis using GENT2 software. Additionally, differences in breast or thyroid tumor compared with normal tissues were also observed in five genes analyzed with GENT2 software that were previously related to sex-influenced cancer according to literature. Finally, the present review points out the need for the development of appropriate free and user-friendly statistical software in order to reduce bias/errors in statistical analyses and overcome researchers’ reluctance to include X-chromosome variants in their genetic-association studies.

Key Words:
  • X-Chromosome
  • X-linked
  • polymorphism
  • cancer
  • gender dimorphism
  • review

The diploid human genome consists of 22 pairs of autosomal chromosomes, which have the same morphology in males and females, and one pair of sex chromosomes (X, Y) that differs between sexes due to the presence of two copies of the X-chromosome in females and in a single copy in males. The Y-chromosome is smaller than the X, representing the 2-3% of the haploid genome, while the X-chromosome represents 5%. The X-chromosome contains approximately 1,500 genes, most of which have no partner on the Y-chromosome. Only a few genes, located in the pseudoautosomal regions of the X-chromosome show homology with the Y-chromosome (1, 2). To ensure equal dosage compensation between sexes, one of the two X-chromosomes in each somatic cell of female mammals is transcriptionally silenced during embryonic development. The X-chromosome inactivation is initiated in the future X-inactivation center, a specific site on the long arm of the X-chromosome that ensures that all but one X-chromosome per diploid genome are inactivated. The whole process is regulated by the X-inactive-specific transcript (Xist) gene which is located in the X-inactivation center. The Xist gene encodes a long non-coding RNA that is expressed by the X-inactive chromosome and coats it in cis. A series of subsequent chromatin modifications, including hypoacetylation of histone H4, accumulation of trimethylated histone H3, K9, and K27, and accumulation of histone variant macroH2A on the X-inactive chromosome, trigger gene silencing. The inactive X-chromosome, also called a Barr body, then localizes to the nuclear periphery. The X-chromosome inactivation occurs randomly either of the maternal or paternal X-chromosome. Therefore, females are a mosaic of two cell populations in which either the maternal or paternal alleles of X-linked genes are expressed. However, over 15% of human X-linked genes escape X-chromosome inactivation and are expressed from both the active and inactive X-chromosomes. Most of these genes lie on the short arm of the X-chromosome and form clusters (3, 4).

The X-chromosome inactivation is related to cancer, as many studies have shown that the inactive X-chromosome is epigenetically unstable in cancer cells. Disappearance of the inactive X-chromosome has been observed in many cancer types and is often accompanied by duplication of the active X-chromosome, while there is evidence for de-condensation and sporadic reactivation of the inactive X-chromosome in cancer cell lines. Both mechanisms lead to overexpression of X-linked genes which may be associated with cancer development and progression (2, 3). Moreover, defects in X-inactivation are common in many malignancies including cancer. Skewed X-chromosome inactivation is a non-random process characterized by the preferential inactivation of one X-chromosome. This process can lead to the expression of recessive traits in females heterozygous for X-linked disorders. A high incidence of skewed X-chromosome inactivation has been reported in females with ovarian, breast and lung cancer, indicating the presence of tumor-related genes on the X-chromosome (5).

Furthermore, loss of heterozygosity (LOH) of X-linked genes is also a common occurrence in carcinogenesis. LOH of tumor-suppressor X-linked genes has been reported in sex-specific cancer such as breast, ovarian and prostate cancer. LOH at the active X-chromosome may lead to the complete loss of function of tumor-suppressor genes, increasing cancer development. LOH of tumor-suppressor X-linked genes has also been associated with tumor aggressiveness in gastroenteropancreatic endocrine tumours (2, 6).

Somatic and germline alterations of genes on sex chromosomes may play a conducive role in tumorigenesis. The X-chromosome carries a significant number of oncogenes, tumor-suppressor genes and tumor-antigen genes. Mutations or dysregulation of these genes might be putative mechanisms for cancer development.

Given the above, we aimed to summarize the polymorphisms of X-linked genes that have been associated with cancer and evaluate their possible implication in sex disparities observed in susceptibility to several types of cancer.

Methodology

PubMed and Web of Sciences databases were searched using the key words “X-chromosome”, “polymorphism” and “cancer”. Then the CancerGenetics web database (http://www.cancergenetics.org) was used and genes associated with cancer in the articles retrieved by the database search were categorized by chromosome. Thereafter, only the genes located on the X-chromosome were selected and a new search for each gene and its genetic association with cancer susceptibility was then performed in PubMed and Web of Science. Thirty-nine articles corresponding to the study’s scope of X-chromosome variants association with cancer susceptibility were published during the period 2005-2020.

Germline Genetic Polymorphisms on the X-Chromosome Involved in Cancer

Genetic variants of genes lying on the X-chromosome have been proposed as candidate factors for increasing cancer susceptibility in a growing number of studies. Table I summarizes the genetic polymorphisms on the X-chromosome that have been associated with cancer risk in case–control studies. Genetic variants which have been detected in patients with cancer and have not been studied in a control group were not included in this review, as their involvement in cancer susceptibility is not clear.

View this table:
  • View inline
  • View popup
Table I.

Genetic polymorphisms of X-chromosomal genes associated with cancer susceptibility.

The X-chromosome can be divided into six different strata according to the probability of genes escaping inactivation. Strata 1 to 5 contain regions that have very low, low, moderate, high and highest probability of escaping X-chromosome inactivation, respectively. On the other hand, genes located on the pseudoautosomal regions 1 and 2 (PAR1 and PAR2) always escape X-chromosome inactivation (4). The genetic polymorphisms on the X-chromosome that are implicated in cancer susceptibility reviewed here are observed in genes located in PAR1 locus and in strata with very low, low, and high probability of escaping X-chromosome inactivation.

Genetic Polymorphisms of Genes Located in the PAR1

Cluster of differentiation 99 (CD99). CD99 gene is a protein-coding gene which is located in PAR1 of X- and Y-chromosomes and escapes X-chromosome inactivation. This gene encodes a cell-surface glycoprotein involved in leukocyte migration, transport of surface molecules, T-cell adhesion, differentiation and apoptosis (7-9). High CD99 expression is a key clinical feature of patients with Ewing sarcoma (EWS) and is routinely used as a prognostic marker (10). Martinelli et al. evaluated the single nucleotide polymorphism (SNP) rs311059 C>T in CD99 gene as a predisposing factor for EWS in children in an Italian population. Rs311059 is a non-coding SNP, but it may increase CD99 expression through affecting CD99 epigenetic regulation mechanisms. Another CD99 variant (rs312257) identified in the same study was associated with better event-free survival in EWS patients, but more studies are needed to validate this finding (11).

Genetic Polymorphisms in Genes With Very Low Probability of Escaping X-Chromosome Inactivation

Angiotensin II receptor type 2 gene (AGTR2). An increasing number of studies have shown that the components of the renin–angiotensin system play a role in tumorigenesis. Angiotensin II is the main effector of the renin–angiotensin system acting through G-protein-coupled receptors, type 1 (AGTR1) and type 2 (AGTR2). AGTR2 protein promotes tumor development by enhancing both malignant cell proliferation and tumor angiogenesis in renal cell carcinoma, gastric cancer and breast cancer (12-14). On the other hand, AGTR2 expression is inversely correlated with cell proliferation and migration in colorectal cancer (15). A genetic variant in the AGTR2 gene, rs5194 G>A, has been associated with aldosterone-producing adenoma. This SNP is located in the 3’-untranslated region (UTR) of the AGTR2 gene. The risky A-allele may enhance the binding of AGTR2 mRNA to micro-RNAs and lead to down-regulation of AGTR2 mRNA, which may stimulate hyperplasia and overgrowth of adrenal cortical cells in patients with aldosterone-producing adenoma (16).

Androgen receptor (AR). Extensive evidence has highlighted the role of this gene in cancer susceptibility. This gene codes for AR, a steroid hormone receptor that acts as a transcriptional factor in androgen signaling. Up-regulation of the AR gene promotes tumorigenesis in many cancer types, including prostate, bladder, kidney cancer, lung, breast and liver cancer but its role in cancer metastasis is contradictory, acting either as a suppressor or stimulator (17). A trinucleotide cytosine-adenine-guanine (CAG) repeat expansion in exon 1 of the AR gene has been associated with cancer risk in different populations. Specifically, the CAG length is inversely correlated with transcriptional activity of the AR gene, meaning that short CAG repeats might promote tumorigenesis. These CAG repeats might serve as a biomarker of prostate cancer predisposition, especially in Asians and Caucasians, as carriers of short CAG repeat expansions have increased susceptibility to prostate cancer (18, 19).

Furthermore, a meta-analysis revealed short CAG repeat length to be associated with ovarian cancer risk in African Americans and Chinese, whereas the reverse association was observed in Caucasians and Italians, again, more studies are needed to validate these results (20). Moreover, a meta-analysis implicated CAG repeats in predisposition to breast cancer, with long CAG repeats increasing the risk of breast cancer in Caucasian women (21). Regarding CAG repeats in colorectal cancer, the findings are inconsistent, as long CAG repeats were associated with higher colorectal cancer risk in one study (22) and with increased colon cancer risk only in males (23), whereas no association between CAG repeats and colorectal cancer was revealed in another study (24).

In addition, exon 1 of the AR gene contains also a GGN microsatellite repeat polymorphism, the length of which varies among different populations. Short GGN repeat length has been reported to enhance AR expression (25). The association of this polymorphism with prostate cancer risk is unclear, as the results of two meta-analyses are contradictive. One study demonstrated that short GGN repeat length was associated with increased risk of prostate cancer, especially in Caucasians (19), while another meta-analysis revealed no association between GGN repeat length and prostate cancer susceptibility (26).

Glypican 3 (GPC3) and GPC4. Genetic polymorphisms in GPC3 and GPC4 have also been related to cancer susceptibility. These genes encode the GPC3 and GPC4 heparan sulfate proteoglycans involved in proliferation, migration, and cell survival modulation in several tissues. GPC3 gene has controversial roles in cancer development, acting either as a tumor-suppressor gene in breast cancer, mesothelioma and ovarian cancer, or as an oncogene in other cancer types such as hepatocellular carcinoma (HCC), colorectal cancer, melanoma, Wilms tumor, neuroblastoma and salivary gland tumors (27, 28). A genetic polymorphism (rs2267531 G>C) in the promoter region of GPC3 was associated with HCC in Egyptians. The risky allele C was found at a significantly higher frequency in patients with HCC compared to the control group and the C allele was correlated with higher GPC3 gene expression (28).

Another member of the glypican gene family, the GPC4 gene, is also involved in cancer risk. The SNP rs1048369 C>T of GPC4 leads to the coding amino acid Ala-Val (p.Ala442Val) mutation and its relationship with cancer susceptibility was studied in Chinese populations. The T-allele of rs1048369 was proposed as risk factor for Epstein– Barr virus-associated gastric cancer by influencing WNT signaling (29), while the C-allele was significantly more frequent in patients with Epstein–Barr virus-positive nasopharyngeal carcinoma (NPC) (30). This difference may be attributed to the different interaction of Epstein–Barr virus with GPC4 in different cancer types; the exact mechanism needs further investigation (30).

Interleukin-1 receptor-associated kinase 1 (IRAK1). IRAKs constitute a family of serine-threonine kinases involved in the signaling cascades of toll-like receptors (TLRs) and interleukin-1 receptors. The first member of the family, IRAK1, has a crucial role in cancer, as its expression is elevated in many solid tumor types and hematological malignancies and is often correlated with metastasis or poor prognosis (31, 32). A recent study in a Greek population correlated the genetic polymorphism rs3027898 C>A, in the 3΄-UTR of IRAK1 with papillary thyroid cancer (PTC) risk. The frequency of the minor allele A was higher in patients with PTC compared to controls, and after adjusting for sex, the A-allele was found to be the risky allele only in men, suggesting a possible role of rs3027898 in PTC development (32). The same polymorphism was also associated with autoimmune diseases in a large number of studies (33-36).

L1 cell-adhesion molecule (L1CAM). A key factor in tumorigenesis in many cancer types, this gene encodes L1CAM transmembrane protein, which is a neuronal cell adhesion molecule involved in cell migration, adhesion and differentiation (37). L1CAM gene has a significant role in cancer initiation and progression, as alterations in its expression can affect cancer cell migration, invasion, growth and metastasis (38, 39). An L1CAM intron SNP, rs4646263 C>A, was associated with susceptibility for epithelial ovarian cancer. Carriers of the AA genotype were at higher risk of developing epithelial ovarian cancer but the mechanism involved remains unclear (40).

Melanoma antigen gene A1 (MAGEA1) and MAGEA11. The MAGE gene family is a known for its role in cancer as its members are tumor biomarkers and targets of immunotherapies. Type I MAGEs (MAGEA, -B, and -C subfamily members) are cancer testis antigens located on the X-chromosome and involved in cancer immunity (41). Genetic association between MAGEs and cancer susceptibility was revealed in two case–control studies. In the first study, the minor T-allele of the rs3788749 SNP on MAGEA1 was more frequent in patients with colorectal cancer and when tumor location was taken into account, this correlation was observed only in patients with rectal cancer. Thus, the rs3788749 C>T polymorphism was proposed as a rectal cancer biomarker, since the T-allele seems to increase MAGEA1 gene expression through its independent functioning as a binding site for transcription factors (42).

The second study identified an association between two intronic SNPs (rs6641352 T>C and rs6540341 C>T) on MAGEA11 gene and renal cell carcinoma (RCC) risk. Carriers of the minor alleles of these SNPs, C and T, respectively, showed increased susceptibility to RCC compared to those homozygous for the major alleles, indicating a possible contribution of these two SNPs to RCC development (43).

Proteasome 26S subunit non-ATPase 10 (PSMD10). PSMD10, encoding the enzyme also known as gankyrin, is a component of the 19S regulatory cap of the 26S proteasome which is involved in diverse biological processes, including cellular growth, proliferation, and invasion. Several studies have reported that PSMD10 gene is up-regulated in a variety of cancer types and have established its role as a candidate oncogene and a tumor biomarker (44-47). Liu et al. investigated the involvement of a SNP located in the 3΄UTR of PSMD10 gene (rs111638916 G>A) in gastric cancer development. They concluded that the minor A-allele of rs111638916 may act as a tumor-promoting factor and increase gastric cancer risk through affecting post-transcriptional regulation of PSMD10 mRNA by miR-505. Carriers of the GA and AA genotypes had also larger tumor size and higher risk of metastasis, suggesting an association between the rs111638916 SNP and clinical features of gastric cancer (48).

Transcription elongation factor A-like 7 (TCEAL7). This gene codes for the cell death-regulatory protein TCEAL7, which acts as a transcriptional repressor of nuclear factor-kappa-B signaling. It has been reported that the TCEAL7 gene is down-regulated in ovarian, breast, brain, prostate, non-small-cell lung and gastric cancer, as well as glioblastoma, and may function as a tumor-suppressor gene (49). In a case–control study, Peedicayil et al. reported three SNPs (rs5987515, rs5987724, rs5945971) upstream of the TCEAL7 gene that may affect ovarian cancer susceptibility. They found that the minor alleles of these SNPs were significantly associated with reduced risk of invasive serous ovarian cancer, and therefore they may have a role in the development of this cancer type (50).

X-linked inhibitor of apoptosis protein (XIAP). Genes of the XIAP apoptotic signaling pathways are also implicated in tumorigenesis. XIAP inhibits cell death mainly through blocking apoptosis. Overexpression of XIAP has been validated in many cancer types and has been linked to cancer development and poor prognosis (51-55). Furthermore, SNP rs8371 C>T in the 3’-UTR of the XIAP gene was associated with esophageal squamous cell carcinoma susceptibility in a Chinese case–control study. The T-allele was observed at lower frequencies in patients compared to the control group, suggesting its protective role in susceptibility (56).

Genetic Polymorphisms in Genes With a Low Probability of Escaping X-Chromosome Inactivation

Factor 9 gene (F9). An X chromosome-wide association study for SNPs in a Chinese population (57) revealed genetic association of F9 with NPC risk, which was validated in Taiwanese (58) and Malaysian replication cohorts (59, 60). This gene encodes factor IX protein, a plasma serine protease which circulates as a zymogen and is involved in blood coagulation (61). Combined analysis of the three population groups revealed that an intron F9 polymorphism, rs371000 C>T, was associated with NPC risk only in males (57).

Fibroblast growth factor 13 (FGF13). The FGF gene family has a crucial role in regulating cellular proliferation, migration, and differentiation. FGF13 protein has an oncogenic activity, as its overexpression is involved in tumor development and progression in many cancer types, including pancreatic endocrine carcinoma, melanoma, multiple myeloma and lung cancer (62). Furthermore, in a genome-wide association study, the intron FGF13 rs619373 G>A variant was associated with increased breast cancer risk in BRCA2 DNA repair-associated (BRCA2) mutation carriers, with the A-allele being the risky variant (63).

Forkhead box P3 (FOXP3). FOXP3 encodes a transcription factor involved in regulation, activation, and differentiation of T-cells. Alterations in FOXP3 expression were found in autoimmune diseases, benign tumors, and carcinomas. FOXP3 is up-regulated in colorectal cancer, non-small lung cancer, thyroid cancer, melanoma and cervical cancer. On the other hand, high levels of FOXP3 are associated with good prognosis in breast, prostate and gastric cancer (64). The association of two FOXP3 promoter polymorphisms, rs3761549 C>T and rs3761548 C>A, with cancer susceptibility has been investigated in many studies in Asian populations but the results were conflicting (65-69). However, a meta-analysis of these studies revealed the rs3761549 (C>T) and rs3761548 (C>A) polymorphisms not to be associated with the risk of breast cancer but with the risk of HCC and non-small-cell lung cancer, respectively (70). Additional studies indicated that the minor A-allele of rs3761548 is a risk factor for colorectal cancer and differentiated thyroid cancer (71, 72), while it is related to lower risk of endometrial cancer (73). Moreover, the same allele was associated with autoimmune diseases susceptibility (74, 75). Regarding the rs3761549 polymorphism, although the major C-allele has been associated with HCC risk, a study in an Iranian population revealed a possible involvement of the T-allele in susceptibility to lung cancer (76). These results might be explained by the dual role of FOXP3 gene in carcinogenesis, acting either as a transcriptional activator or repressor (73, 76). Another FOXP3 promoter polymorphism, rs5902434 (del/ATT), and especially the ATT/ATT genotype, may act as a protective factor reducing endometrial cancer risk in Chinese women (73). The same polymorphism has also been associated with low risk of recurrent respiratory papillomatosis, a benign neoplasm of the larynx and trachea (77). Additionally, the intron FOXP3 rs220883 T>C polymorphism appeared to reduce the risk of differentiated thyroid cancer (C-allele) (72) and to increase the susceptibility to hepatitis B-related HCC and small-cell lung cancer (T-allele) (66, 76). Finally, the heterozygous genotype of the intronic rs2294021 C>T polymorphism was reported to interact with skewed X-chromosome inactivation and elevate breast cancer predisposition by breaking the balance between FOXP3-controlled immune tolerance and tumor suppression (68).

Monoamine oxidase-A (MAOA). This gene encodes the mitochondrial enzyme which degrades monoamine neurotransmitters, such as serotonin and norepinephrine, by the production of hydrogen peroxide. Previous studies have documented that up-regulation of the MAOA gene promotes cancer development and progression in prostate cancer, renal cell carcinoma, classical Hodgkin lymphomas, glioma and non-small cell lung cancer, while reduced MAOA levels may serve as a biomarker for cholangioma and HCC prognosis (78). A recent study proposed the rs144551722 G>A polymorphism, which lies in the promoter region of the MAOA gene, as a predictive biomarker for glioblastoma in males (79).

Nudix hydrolase 10 (NUDT10) and NUDT11. NUDT10 and NUDT11 genes encode two diphosphoinositol polyphosphate phosphohydrolases involved in a variety of biological processes, including vesicle trafficking, maintenance of cell wall integrity, and mediation of cellular stress responses (80). A meta-analysis assessed that a NUDT10 -NUDT11 intergenic polymorphism, rs5945572, is associated with prostate cancer susceptibility. More specifically, the minor G-allele of rs5945572 increases prostate cancer susceptibility and may promote prostate carcinogenesis via multiple signaling pathways (81). This association was confirmed not only in patients with sporadic, but also in those with hereditary prostate cancer (82). Another SNP in the same genetic region, rs5945619, was also reported to be associated with prostate cancer risk in several studies, suggesting a significant role of the NUDT10-NUDT11 intergenic region in prostate cancer susceptibility (83-85).

Tissue inhibitor matrix metalloproteinase 1 (TIMP1). TIMP1 gene inhibits the proteolytic activity of matrix metalloproteinases and is involved in cell proliferation and anti-apoptotic activity. TIMP1 overexpression is associated with cancer progression and poor patient prognosis in papillary thyroid carcinoma, cutaneous melanoma, and gastric, breast, lung and colorectal cancer (86). The rs4898 T>C TIMP1 missense variant has been proposed as a predictive marker for breast and lung cancer, as the C-allelic frequency was increased in patients of both cancer types compared to controls in a Taiwanese population (87, 88). After adjusting for gender, the distribution of rs4898 genotypes did not differ significantly between males and females, so this polymorphism was reported not to contribute to the sex disparities in lung cancer susceptibility (88).

Genetic Polymorphisms in Genes With a High Probability of Escaping X-Chromosome Inactivation

Ras homolog GTPase-activating protein 6 (ARHGAP6). ARHGAP6 is a novel protein involved in regulation of actin polymerization in several cellular processes. It has been reported in in vitro and in vivo studies that ARHGAP6 has an inhibitory effect on the cell growth and metastasis of cervical carcinoma and lung cancer (89, 90) and might serve as a biomarker for colorectal cancer development and progression (91). An intron SNP on ARHGAP6 gene (rs5933886) showed correlation to NPC predisposition, but only in females (57).

Duchenne muscular dystrophy (DMD). This gene is the largest human gene and codes for dystrophin protein, which is part of a protein complex that links the intracellular cytoskeleton network to the extracellular matrix. DMD dysregulation is involved in the pathogenesis of sarcoma, leukemia, lymphoma, melanoma, carcinoma and nervous system cancer (92). In an X-chromosome-wide association study, the intron SNP rs5927056 T>G on the DMD gene was associated with NPC susceptibility, with the minor G allele to be the risky variant. This polymorphism might alter regulatory motifs and affect DMD expression and thus contribute to NPC predisposition (57).

Shroom family member 2 (SHROOM2). A meta-analysis of five genome-wide association studies revealed an association of the rs5934683 polymorphism in the promoter region of the SHROOM2 gene with colorectal cancer susceptibility (93). The SHROOM2 gene is involved in endothelial sprouting, migration, and angiogenesis. The SHROOM2 gene is implicated in carcinogenesis of esophageal squamous cell carcinoma and NPC, acting as a tumor-suppressor gene (94). Moreover, a meta-analysis identified a correlation between the SHROOM intron SNP rs2405942 A>G and prostate cancer risk, which was then confirmed in the replication stage of the same study (95). However, an association study by Cremers et al. did not validate this finding (82).

Toll-like receptor 7 (TLR7). This gene encodes an endosomal receptor that has a key role in innate and adaptive immunity. This protein has been studied due to its immunostimulatory action that can be used in antitumor therapy (96). The rs179008 A>T TLR7 polymorphism has been proposed to have a protective effect on the risk of Hodgkin disease in individuals carrying the minor T-allele (97). Another TLR7 SNP, rs179019 A>C, has been associated with increased susceptibility to urinary bladder cancer (UBC) in males, but more studies are needed to confirm this finding (96). This polymorphism has also been proposed as a predisposing factor for systemic lupus erythematosus (98, 99).

Interaction Between Genes Involved in Cancer Susceptibility

The study of the interactions among the genes described above may provide a better overview of their implication in cancer susceptibility. GeneMANIA (http://genemania.org) is a flexible user-friendly web site for generating hypotheses about gene function, analyzing gene lists and prioritizing genes for functional assays. The 22 corresponding genes from Table I were submitted to GeneMANIA and their interaction network is shown in Figure 1. The interaction network shows direct and indirect interactions among the 22 genes (co-expression, shared protein domains, co-localization, pathway, and predicted interactions). Co-expression means that two genes are linked if their expression levels are similar across conditions in a gene-expression study. Shared protein domains are a protein interaction type in which the genes are linked because their protein products have the same protein domain. Moreover, two genes are considered to be ‘linked’ if they are both expressed in the same tissue or identified in the same cellular location (co-localization) or if their products participate in the same reaction within a pathway (pathway). Finally, the interaction network shows the predicted functional relationships between genes, which may be protein interactions.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Interaction network of the 22 X-chromosome-linked genes (left column), the polymorphisms of which are involved in cancer susceptibility. The right column shows other genes which participate in the indirect interactions among the 22 X-linked genes (http://genemania.org).

In detail, CD99 shows similar expression level to IRAK1, TIMP1 and GPC4, and has the same protein domain and predicted interaction with IRAK1. Regarding the heparan sulfate proteoglycans GPC3 and GPC4, GPC3 has a similar expression level to DMD, SHROOM2, MAGEA1 and MAOA, while GPC4 shows co-expression with CD99 and DMD. GPC3 and GPC4 also share the same protein domain. AR is co-expressed with DMD and participates in the same pathway with F9. SHROOM2 has similar expression levels to GPC3 and MAOA and the same protein location as MAGEA1. Furthermore, MAGEA1 and MAGEA11 are co-expressed and share the same protein domain, while MAGEA1 also has the same protein location as SHROOM2 and L1CAM. Co-expression is also observed between XIAP and PMSD10. Moreover, IRAK1 participates in the same pathway as TLR7 and has predicted interaction with XIAP. From the remaining genes, FOXP3, TCEAL7 and NUTD11 show only indirect interactions in the network, while FGF13, AGTR2 and ARHGAP6 have neither direct nor indirect interactions (Figure 1).

The multiple interactions among the 22 genes described in Table I demonstrate the complicated way in which these genes are involved in cancer susceptibility and illustrate that these genes may contribute to tumorigenesis through their interplay. A gene polymorphism may not contribute to cancer susceptibility directly, but it is possible that it can affect cancer development, indirectly affecting expression of other genes. Specifically, alterations in gene expression caused by a polymorphism can affect the expression of other genes participating in the same pathway or alter the balance among genes that are co-expressed, promoting tumorigenesis, Moreover, a combination of genetic variants in genes that interact with each other may promote tumorigenesis. Taking into account that most of these genes are located in regions with low or very low probability of escaping X-chromosome inactivation, random or skewed X-chromosome inactivation events further complicate the understanding of the mechanisms involved in cancer development.

Sexual Dimorphism in Cancer

Sex is a significant factor that affects the incidence, progression and treatment responses of various diseases including cancer. Sex disparities have been observed not only in sex-specific cancer, but also in a variety of other cancer types. Generally, there is a male predominance in cancer susceptibility for many cancer types, such as hematological malignancies, head and neck squamous cell cancer, and esophageal, urinary bladder and liver cancer. On the other hand, females have an increased risk of developing thyroid, gallbladder, biliary tract and anal cancer (100). Sex disparities in cancer susceptibility are believed to be the result of both physiological and genomic differences between the sexes (101).

Physiological differences. The main reason for the physiological differences leading to different cancer susceptibility between males and females is sex hormones. Sex steroid hormones derive from cholesterol and include the androgens (testosterone), estrogens (17β-estradiol, estriol, and estrone) and progestogens. Sex hormones act through four types of receptors: the estrogen receptors ERα, ERβ and G protein-coupled estrogen receptor 1 (GPER1), and the AR. By binding to these receptors, sex hormones are involved in cell-signaling pathways affecting cancer susceptibility through various mechanisms (101). Most of these mechanisms influence immune surveillance, cancer stem cell self-renewal, the tumor microenvironment, and the regulation of systemic metabolism. In many cancer types, such as head and neck squamous cell carcinoma, colonic, glioma, skin, esophageal and non-small-cell lung cancer, significant differences in incidence are observed when comparing males or postmenopausal females with premenopausal females, suggesting a mechanism of sex hormone-mediated tumor development (102). Sex hormone signaling often has controversial roles in regulating cancer development. For example, estrogen signaling has a protective role in HCC, reducing the cancer risk in females, while in many other cancer types, such as of the breast and the female reproductive system, it promotes carcinogenesis (103). Moreover, studies have shown that sex-related hormones, such as prolactin, gonadotropins (Luteinizing hormone and Follicle stimulation hormone) and gonadotropin-releasing hormone have a role in tumor development in prostate, ovarian and breast cancer (102).

Genomic differences. The main reason for the genomic differences in cancer susceptibility between sexes is the sex chromosomes. As described previously, the X-chromosome carries a significant number of genes involved in tumorigenesis. The presence of these genes in a single copy in males and in two copies in females, in combination with random, skewed or escaping X-chromosome inactivation events and LOH in females, is a mechanism that explains the differences in cancer predisposition between sexes. Alterations on the Y-chromosome, sex-specific expression of protein-coding genes and micro-RNAs, and differences in epigenetic profiles of autosomal and sex chromosome genes can also alter the cancer incidence rate between males and females (101). This part of the review focuses on the possible implication of genetic polymorphisms on the X-chromosome, described above, in sex disparities in cancer susceptibility.

Polymorphisms on the X-chromosome and sex disparities in cancer susceptibility. Polymorphisms in eight genes (AR, FGF13, FOXP3, L1CAM, NUDT11, SHROOM, TCEAL7, TIMP1) described in Table I were associated with sex-specific cancer, such as prostate cancer in males, and breast or ovarian cancer in females (referred to as sex-restricted in Table II).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Differences in expression profiles of X-chromosome genes associated with cancer between normal and breast or thyroid tumor tissues (http://gent2.appex.kr).

As far as sex-influenced cancer, Jiang et al. reported that the frequency of the AA or AC genotypes of the FOXP3 rs3761548 (C>A) polymorphism was increased in females compared to males. These genotypes were associated with differentiated thyroid cancer risk (72). Taking into account that thyroid cancer incidence has a male to female ratio of 1:4 (100), rs3761548 may explain the increased incidence of thyroid cancer in females. Moreover, the rs3027898 risky A-allele on the IRAK1 gene was correlated with PTC risk in males. In male controls, the major rs3027898 C-allele was more frequent compared to in females, leading to high IRAK1 expression, which may act as a protective factor for PTC in males (32).

Another SNP, rs179019, on the TLR7 gene may increase UBC susceptibility in males. In females, no significant difference in the allelic frequency for rs179019 was observed between patients with UBC and the control group (96). As UBC has higher prevalence in males compared to females, with a male to female ratio of 4:1 (96), it is of great importance to investigate the possible role of the rs179019 polymorphism in increasing UBC risk in males.

Furthermore, two other polymorphisms of the MAGEA11 gene (rs6641352 T>C and rs6540341 C>T) were associated with RCC risk in the overall population and after performing gender-stratified analysis, rs6641352 showed stronger association with RCC in males, in contrast to rs6540341 in females (43). RCC frequency did not differ much between sexes (male to female ratio 1.5:1) (43), therefore more studies are needed to confirm these findings and clarify how these polymorphisms contribute to RCC cancer risk in the two sexes.

Additionally, the study of Zuo et al. revealed two X-linked SNPs, rs371000 C>T on the F9 gene and rs5933886 on the ARHGAP6 gene to be associated with NPC susceptibility. The rs371000 polymorphism was shown to increase risk of NPC only in males, while rs5933886 had a protective effect on NPC risk in females. Given that there is a male predominance in NPC incidence (male to female ratio of 2-3:1), these polymorphisms may contribute to the gender disparities in NPC susceptibility (57).

Finally, the rs144551722 G>A polymorphism on the MAOA gene was associated with glioblastoma risk only in males. As glioma is more common in males compared to females (male to female ratio 1.4:1), this SNP might have a role in the differences observed in glioma risk between sexes (79).

A confirmation of the sex-associated involvement of the above reviewed genetic polymorphisms in cancer susceptibility may be indirectly derived from studying gene expression in normal compared to certain tumor tissues. Taking as examples breast cancer and thyroid cancer, a female-specific cancer and a cancer with high female to male incidence ratio, respectively, the expression levels of the sex-influenced and sex-restricted genes described above were studied in breast and thyroid cancer. Specifically, for this analysis the GENT2 database (http://gent2.appex.kr) was used, which is a platform for exploring gene-expression patterns across normal and tumor tissues. Most of these genes have significantly altered expression in breast or thyroid tumor compared with normal tissues as shown in Table II. Thus, this finding may enforce the association of some of the genes discussed above with sex-limited or sex-influenced cancer types.

Statistical Analysis of X-Chromosome Genetic Association Studies

In case–control genetic association studies, many statistical methods for testing the association between autosomal markers and phenotype have successfully been established. However, due to the different inheritance patterns of X-chromosome-linked traits and the X-chromosome inactivation process, there is a lack of statistical tools for handling X-chromosome genotypic data. As a result, in most studies, the X-chromosomal variants are either incorrectly analyzed or completely excluded from analysis. Recently, many statistical models for testing X-chromosomal associations have been developed. Zheng et al. proposed several approaches for analyzing X-chromosomal variants (104) and Clayton was the first who incorporated the random X-inactivation process in X-chromosome data analysis (105). Other methods have taken into account the different patterns of X-chromosome inactivation and the deviations from Hardy–Weinberg equilibrium (106). Different methods for testing Hardy–Weinberg equilibrium on the X-chromosome have also been developed (107). In addition, Gao et al. introduced the XWAS software toolset, which facilitates the integration of X-chromosome data in genome-wide association studies, combining several previously proposed statistical models (108). However, this software does not incorporate the skewed X-chromosome inactivation pattern.

Even though there are efforts to reduce mistakes in X-chromosome genetic association studies, it is obvious that there is a lack of a standardized, complete, and user-friendly method to analyze X-chromosome genomic data. Therefore, current genetic association studies of X-chromosome-linked variants may have bias or errors in their analyses or may conceal the reluctance of researchers to include X-chromosome variants in their studies.

Conclusion

In summary, this study reviewed genetic polymorphisms on the X chromosome that affect cancer susceptibility. Some of these polymorphisms have a sex-specific association with cancer risk. This suggests that the X-chromosome may have different genetic effects on the two sexes, which may partly explain the sexual dimorphism observed in the incidence of many cancer types. It is of primary importance to point out that the statistical analysis of the X-chromosome genotype–phenotype associations is susceptible to bias due to the presence of a single allele in males and non-random, skewed or escaping X-chromosome inactivation events in females. The genes highlighted in this review are located in different regions regarding the X-chromosome inactivation process, with most genes having a high probability of becoming inactivated and fewer genes escaping inactivation. Considering that there is a lack of available tools for analyzing X-chromosome genotypic data and taking into account the specific traits of the X-chromosome inactivation process and inheritance, the need for the development of appropriate free and user-friendly statistical software in order to reduce bias or errors in the resultant associations is great.

Footnotes

  • Authors’ Contributions

    CA and AC were responsible for conducting the literature research, extracting, and analyzing data, interpreting results and writing the review. AC, TP and LA reviewed the article.

  • Conflicts of Interest

    None declared.

  • Received February 4, 2022.
  • Revision received March 3, 2022.
  • Accepted March 14, 2022.
  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Helena Mangs A and
    2. Morris BJ
    : The human pseudoautosomal region (PAR): origin, function and future. Curr Genomics 8(2): 129-136, 2007. PMID: 18660847. DOI: 10.2174/138920207780368141
    OpenUrlCrossRefPubMed
  2. ↵
    1. Liao DJ,
    2. Du QQ,
    3. Yu BW,
    4. Grignon D and
    5. Sarkar FH
    : Novel perspective: focusing on the X chromosome in reproductive cancers. Cancer Invest 21(4): 641-658, 2003. PMID: 14533452. DOI: 10.1081/cnv-120022385
    OpenUrlCrossRefPubMed
  3. ↵
    1. Chaligné R and
    2. Heard E
    : X-chromosome inactivation in development and cancer. FEBS Lett 588(15): 2514-2522, 2014. PMID: 24937141. DOI: 10.1016/j.febslet.2014.06.023
    OpenUrlCrossRefPubMed
  4. ↵
    1. Schurz H,
    2. Salie M,
    3. Tromp G,
    4. Hoal EG,
    5. Kinnear CJ and
    6. Möller M
    : The X chromosome and sex-specific effects in infectious disease susceptibility. Hum Genomics 13(1): 2, 2019. PMID: 30621780. DOI: 10.1186/s40246-018-0185-z
    OpenUrlCrossRefPubMed
  5. ↵
    1. Li G,
    2. Su Q,
    3. Liu GQ,
    4. Gong L,
    5. Zhang W,
    6. Zhu SJ,
    7. Zhang HL and
    8. Feng YM
    : Skewed X chromosome inactivation of blood cells is associated with early development of lung cancer in females. Oncol Rep 16(4): 859-864, 2006. PMID: 16969506.
    OpenUrlPubMed
  6. ↵
    1. Spatz A,
    2. Borg C and
    3. Feunteun J
    : X-chromosome genetics and human cancer. Nat Rev Cancer 4(8): 617-629, 2004. PMID: 15286741. DOI: 10.1038/nrc1413
    OpenUrlCrossRefPubMed
  7. ↵
    1. Dworzak MN,
    2. Fritsch G,
    3. Fleischer C,
    4. Printz D,
    5. Fröschl G,
    6. Buchinger P,
    7. Mann G and
    8. Gadner H
    : CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis. Br J Haematol 105(3): 690-695, 1999. PMID: 10354133. DOI: 10.1046/j.1365-2141.1999.01426.x
    OpenUrlCrossRefPubMed
    1. Alberti I,
    2. Bernard G,
    3. Rouquette-Jazdanian AK,
    4. Pelassy C,
    5. Pourtein M,
    6. Aussel C and
    7. Bernard A
    : CD99 isoforms expression dictates T cell functional outcomes. FASEB J 16(14): 1946-1948, 2002. PMID: 12368226. DOI: 10.1096/fj.02-0049fje
    OpenUrlCrossRefPubMed
  8. ↵
    1. Pettersen RD,
    2. Bernard G,
    3. Olafsen MK,
    4. Pourtein M and
    5. Lie SO
    : CD99 signals caspase-independent T cell death. J Immunol 166(8): 4931-4942, 2001. PMID: 11290771. DOI: 10.4049/jimmunol.166.8.4931
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Kovar H,
    2. Dworzak M,
    3. Strehl S,
    4. Schnell E,
    5. Ambros IM,
    6. Ambros PF and
    7. Gadner H
    : Overexpression of the pseudoautosomal gene MIC2 in Ewing’s sarcoma and peripheral primitive neuroectodermal tumor. Oncogene 5(7): 1067-1070, 1990. PMID: 1695726.
    OpenUrlPubMed
  10. ↵
    1. Martinelli M,
    2. Parra A,
    3. Scapoli L,
    4. De Sanctis P,
    5. Chiadini V,
    6. Hattinger C,
    7. Picci P,
    8. Zucchini C and
    9. Scotlandi K
    : CD99 polymorphisms significantly influence the probability to develop Ewing sarcoma in earlier age and patient disease progression. Oncotarget 7(47): 77958-77967, 2016. PMID: 27792997. DOI: 10.18632/oncotarget.12862
    OpenUrlCrossRefPubMed
  11. ↵
    1. Dolley-Hitze T,
    2. Jouan F,
    3. Martin B,
    4. Mottier S,
    5. Edeline J,
    6. Moranne O,
    7. Le Pogamp P,
    8. Belaud-Rotureau MA,
    9. Patard JJ,
    10. Rioux-Leclercq N and
    11. Vigneau C
    : Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer 103(11): 1698-1705, 2010. PMID: 21102591. DOI: 10.1038/sj.bjc.6605866
    OpenUrlCrossRefPubMed
    1. Carl-McGrath S,
    2. Ebert MP,
    3. Lendeckel U and
    4. Röcken C
    : Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread. Cancer Biol Ther 6(8): 1218-1226, 2007. PMID: 18059164. DOI: 10.4161/cbt.6.8.4412
    OpenUrlCrossRefPubMed
  12. ↵
    1. De Paepe B,
    2. Verstraeten VM,
    3. De Potter CR and
    4. Bullock GR
    : Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem Cell Biol 117(1): 13-19, 2002. PMID: 11819093. DOI: 10.1007/s00418-001-0356-0
    OpenUrlCrossRefPubMed
  13. ↵
    1. Zhou L,
    2. Luo Y,
    3. Sato S,
    4. Tanabe E,
    5. Kitayoshi M,
    6. Fujiwara R,
    7. Sasaki T,
    8. Fujii K,
    9. Ohmori H and
    10. Kuniyasu H
    : Role of two types of angiotensin II receptors in colorectal carcinoma progression. Pathobiology 81(4): 169-175, 2014. PMID: 25138435. DOI: 10.1159/000362092
    OpenUrlCrossRefPubMed
  14. ↵
    1. Ouyang J,
    2. Wu Z,
    3. Xing J,
    4. Yan Y,
    5. Zhang G,
    6. Wang B,
    7. Li H,
    8. Ma X and
    9. Zhang X
    : Association of polymorphisms in angiotensin II receptor genes with aldosterone-producing adenoma. J Huazhong Univ Sci Technolog Med Sci 31(3): 301, 2011. PMID: 21671168. DOI: 10.1007/s11596-011-0371-x
    OpenUrlCrossRefPubMed
  15. ↵
    1. Chang C,
    2. Lee SO,
    3. Yeh S and
    4. Chang TM
    : Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene 33(25): 3225-3234, 2014. PMID: 23873027. DOI: 10.1038/onc.2013.274
    OpenUrlCrossRefPubMed
  16. ↵
    1. Qin Z,
    2. Li X,
    3. Han P,
    4. Zheng Y,
    5. Liu H,
    6. Tang J,
    7. Yang C,
    8. Zhang J,
    9. Wang K,
    10. Qi X,
    11. Tang M,
    12. Wang W and
    13. Zhang W
    : Association between polymorphic CAG repeat lengths in the androgen receptor gene and susceptibility to prostate cancer: A systematic review and meta-analysis. Medicine (Baltimore) 96(25): e7258, 2017. PMID: 28640128. DOI: 10.1097/MD.0000000000007258
    OpenUrlCrossRefPubMed
  17. ↵
    1. Weng H,
    2. Li S,
    3. Huang JY,
    4. He ZQ,
    5. Meng XY,
    6. Cao Y,
    7. Fang C and
    8. Zeng XT
    : Androgen receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. Sci Rep 7: 40554, 2017. PMID: 28091563. DOI: 10.1038/srep40554
    OpenUrlCrossRefPubMed
  18. ↵
    1. Deng Y,
    2. Wang J,
    3. Wang L and
    4. Du Y
    : Androgen receptor gene CAG repeat polymorphism and ovarian cancer risk: A meta-analysis. Biosci Trends 11(2): 193-201, 2017. PMID: 28250337. DOI: 10.5582/bst.2016.01229
    OpenUrlCrossRefPubMed
  19. ↵
    1. Mao Q,
    2. Qiu M,
    3. Dong G,
    4. Xia W,
    5. Zhang S,
    6. Xu Y,
    7. Wang J,
    8. Rong Y,
    9. Xu L and
    10. Jiang F
    : CAG repeat polymorphisms in the androgen receptor and breast cancer risk in women: a meta-analysis of 17 studies. Onco Targets Ther 8: 2111-2120, 2015. PMID: 26316780. DOI: 10.2147/OTT.S85130
    OpenUrlCrossRefPubMed
  20. ↵
    1. Huang R,
    2. Wang G,
    3. Song Y,
    4. Wang F,
    5. Zhu B,
    6. Tang Q,
    7. Liu Z,
    8. Chen Y,
    9. Zhang Q,
    10. Muhammad S and
    11. Wang X
    : Polymorphic CAG repeat and protein expression of androgen receptor gene in colorectal cancer. Mol Cancer Ther 14(4): 1066-1074, 2015. PMID: 25637315. DOI: 10.1158/1535-7163.MCT-14-0620
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Slattery ML,
    2. Sweeney C,
    3. Murtaugh M,
    4. Ma KN,
    5. Wolff RK,
    6. Potter JD,
    7. Caan BJ and
    8. Samowitz W
    : Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 14(12): 2936-2942, 2005. PMID: 16365013. DOI: 10.1158/1055-9965.EPI-05-0514
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Rudolph A,
    2. Shi H,
    3. Försti A,
    4. Hoffmeister M,
    5. Sainz J,
    6. Jansen L,
    7. Hemminki K,
    8. Brenner H and
    9. Chang-Claude J
    : Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: results from a German population-based case-control study. BMC Cancer 14: 817, 2014. PMID: 25376484. DOI: 10.1186/1471-2407-14-817
    OpenUrlCrossRefPubMed
  23. ↵
    1. Ding D,
    2. Xu L,
    3. Menon M,
    4. Reddy GP and
    5. Barrack ER
    : Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action. Prostate 62(2): 133-139, 2005. PMID: 15389799. DOI: 10.1002/pros.20128
    OpenUrlCrossRefPubMed
  24. ↵
    1. Li J,
    2. Xiao F,
    3. Zhang Y,
    4. Lan A,
    5. Song Q,
    6. Zhang R,
    7. Gu K,
    8. Chen P,
    9. Li Z,
    10. Zhang X and
    11. Yang X
    : Shorter GGN repeats in androgen receptor gene would not increase the risk of prostate cancer. Technol Cancer Res Treat 16(2): 159-166, 2017. PMID: 28279145. DOI: 10.1177/1533034616673272
    OpenUrlCrossRefPubMed
  25. ↵
    1. Andisheh-Tadbir A,
    2. Ashraf MJ,
    3. Gudarzi A and
    4. Zare R
    : Evaluation of Glypican-3 expression in benign and malignant salivary gland tumors. J Oral Biol Craniofac Res 9(1): 63-66, 2019. PMID: 30294537. DOI: 10.1016/j.jobcr.2018.09.002
    OpenUrlCrossRefPubMed
  26. ↵
    1. Motawi TMK,
    2. Sadik NAH,
    3. Sabry D,
    4. Shahin NN and
    5. Fahim SA
    : rs2267531, a promoter SNP within glypican-3 gene in the X chromosome, is associated with hepatocellular carcinoma in Egyptians. Sci Rep 9(1): 6868, 2019. PMID: 31053802. DOI: 10.1038/s41598-019-43376-3
    OpenUrlCrossRefPubMed
  27. ↵
    1. Zhao D,
    2. Liu S,
    3. Sun L,
    4. Zhao Z,
    5. Liu S,
    6. Kuang X,
    7. Shu J and
    8. Luo B
    : Glypican-4 gene polymorphism (rs1048369) and susceptibility to Epstein-Barr virus-associated and -negative gastric carcinoma. Virus Res 220: 52-56, 2016. PMID: 27071854. DOI: 10.1016/j.virusres.2016.04.005
    OpenUrlCrossRefPubMed
  28. ↵
    1. Liu S,
    2. Liu W,
    3. Zhao D,
    4. Zhang Y,
    5. Zhao Z and
    6. Luo B
    : The Glypican-4 gene polymorphism rs1048369 and susceptibility to Epstein-Barr virus-positive and -negative nasopharyngeal carcinoma in Northern China. Oncol Res Treat 42(11): 572-579, 2019. PMID: 31522169. DOI: 10.1159/000502753
    OpenUrlCrossRefPubMed
  29. ↵
    1. Singer JW,
    2. Fleischman A,
    3. Al-Fayoumi S,
    4. Mascarenhas JO,
    5. Yu Q and
    6. Agarwal A
    : Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. Oncotarget 9(70): 33416-33439, 2018. PMID: 30279971. DOI: 10.18632/oncotarget.26058
    OpenUrlCrossRefPubMed
  30. ↵
    1. Chatzikyriakidou A,
    2. Chorti A and
    3. Papavramidis T
    : Association of IRAK1 gene polymorphism rs3027898 with papillary cancer restricted to the thyroid gland: a pilot study. In Vivo 33(6): 2281-2285, 2019. PMID: 31662568. DOI: 10.21873/invivo.11734
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Song GG,
    2. Bae SC,
    3. Seo YH,
    4. Kim JH,
    5. Choi SJ,
    6. Ji JD and
    7. Lee YH
    : The association between susceptibility to inflammatory arthritis and miR-146a, miR-499 and IRAK1 polymorphisms. A meta-analysis. Z Rheumatol 74(7): 637-645, 2015. PMID: 25269878. DOI: 10.1007/s00393-014-1493-x
    OpenUrlCrossRefPubMed
    1. Shaker OG,
    2. El Boghdady NA and
    3. El Sayed AE
    : Association of MiRNA-146a, MiRNA-499, IRAK1 and PADI4 polymorphisms with rheumatoid arthritis in Egyptian population. Cell Physiol Biochem 46(6): 2239-2249, 2018. PMID: 29734142. DOI: 10.1159/000489592
    OpenUrlCrossRefPubMed
    1. Labib DA,
    2. Shaker OG,
    3. El Refai RM,
    4. Ghoniem SA and
    5. Elmazny A
    : Association between miRNA-146a and polymorphisms of its target gene, IRAK1, regarding susceptibility to and clinical features of systemic lupus erythematous and multiple sclerosis. Lab Med 50(1): 34-41, 2019. PMID: 30060033. DOI: 10.1093/labmed/lmy033
    OpenUrlCrossRefPubMed
  32. ↵
    1. Shi Z,
    2. Chen H,
    3. Du Q,
    4. Zhang Y,
    5. Zhang Q,
    6. Qiu Y,
    7. Zhao Z,
    8. Wang J,
    9. Yang M and
    10. Zhou H
    : IRAK1 polymorphisms are associated with susceptibility to neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 37: 101438, 2020. PMID: 32173002. DOI: 10.1016/j.msard.2019.101438
    OpenUrlCrossRefPubMed
  33. ↵
    1. Samatov TR,
    2. Wicklein D and
    3. Tonevitsky AG
    : L1CAM: Cell adhesion and more. Prog Histochem Cytochem 51(2): 25-32, 2016. PMID: 27267927. DOI: 10.1016/j.proghi.2016.05.001
    OpenUrlCrossRefPubMed
  34. ↵
    1. Altevogt P,
    2. Doberstein K and
    3. Fogel M
    : L1CAM in human cancer. Int J Cancer 138(7): 1565-1576, 2016. PMID: 26111503. DOI: 10.1002/ijc.29658
    OpenUrlCrossRefPubMed
  35. ↵
    1. Altevogt P,
    2. Ben-Ze’ev A,
    3. Gavert N,
    4. Schumacher U,
    5. Schäfer H and
    6. Sebens S
    : Recent insights into the role of L1CAM in cancer initiation and progression. Int J Cancer 147(12): 3292-3296, 2020. PMID: 32588424. DOI: 10.1002/ijc.33177
    OpenUrlCrossRefPubMed
  36. ↵
    1. Heubner M,
    2. Wimberger P,
    3. Kasimir-Bauer S,
    4. Otterbach F,
    5. Kimmig R and
    6. Siffert W
    : The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer. Anticancer Res 29(8): 3449-3452, 2009. PMID: 19661372.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Lee AK and
    2. Potts PR
    : A comprehensive guide to the MAGE family of ubiquitin ligases. J Mol Biol 429(8): 1114-1142, 2017. PMID: 28300603. DOI: 10.1016/j.jmb.2017.03.005
    OpenUrlCrossRefPubMed
  38. ↵
    1. Almutairi M and
    2. Semlali A
    : Relationship between melanoma-associated antigen 1 (MAGE-A1) gene polymorphisms and colorectal cancer development. Genet Mol Res 18: 16039940, 2019. DOI: 10.4238/gmr16039940
    OpenUrlCrossRef
  39. ↵
    1. Su S,
    2. Gu Q,
    3. Xu A,
    4. Shen S,
    5. Liu S,
    6. Zhang C,
    7. Miao C,
    8. Qin C,
    9. Liu B and
    10. Wang Z
    : Genetic variations in MAGE-A11 predict the risk and survival of renal cell cancer. J Cancer 10(20): 4860-4865, 2019. PMID: 31598157. DOI: 10.7150/jca.32675
    OpenUrlCrossRefPubMed
  40. ↵
    1. Li J,
    2. Knobloch TJ,
    3. Kresty LA,
    4. Zhang Z,
    5. Lang JC,
    6. Schuller DE and
    7. Weghorst CM
    : Gankyrin, a biomarker for epithelial carcinogenesis, is overexpressed in human oral cancer. Anticancer Res 31(9): 2683-2692, 2011. PMID: 21868508.
    OpenUrlAbstract/FREE Full Text
    1. Kim YH,
    2. Kim JH,
    3. Choi YW,
    4. Lim SK,
    5. Yim H,
    6. Kang SY,
    7. Chung YS,
    8. Lee GY and
    9. Park TJ
    : Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression. Exp Mol Pathol 94(2): 360-365, 2013. PMID: 23276718. DOI: 10.1016/j.yexmp.2012.12.002
    OpenUrlCrossRefPubMed
    1. Wang C,
    2. Li Y,
    3. Chu CM,
    4. Zhang XM,
    5. Ma J,
    6. Huang H,
    7. Wang YN,
    8. Hong TY,
    9. Zhang J,
    10. Pan XW,
    11. Zheng JC,
    12. Jiang N,
    13. Hu CY,
    14. Ma X,
    15. Sun YH and
    16. Cui XG
    : Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma. EBioMedicine 39: 255-264, 2019. PMID: 30558998. DOI: 10.1016/j.ebiom.2018.12.011
    OpenUrlCrossRefPubMed
  41. ↵
    1. Li H,
    2. Zhang J,
    3. Zhen C,
    4. Yang B and
    5. Feng L
    : Gankyrin as a potential target for tumor therapy: evidence and perspectives. Am J Transl Res 10(7): 1949-1960, 2018. PMID: 30093934.
    OpenUrlPubMed
  42. ↵
    1. Liu Y,
    2. Xu J,
    3. Jiang M,
    4. Ni L,
    5. Chen Y and
    6. Ling Y
    : Association between functional PSMD10 Rs111638916 variant regulated by MiR-505 and gastric cancer risk in a Chinese population. Cell Physiol Biochem 37(3): 1010-1017, 2015. PMID: 26394032. DOI: 10.1159/000430227
    OpenUrlCrossRefPubMed
  43. ↵
    1. Orhan C,
    2. Bulut P,
    3. Dalay N,
    4. Ersen E and
    5. Buyru N
    : Downregulation of TCEAL7 expression induces CCND1 expression in non-small cell lung cancer. Mol Biol Rep 46(5): 5251-5256, 2019. PMID: 31321645. DOI: 10.1007/s11033-019-04982-6
    OpenUrlCrossRefPubMed
  44. ↵
    1. Peedicayil A,
    2. Vierkant RA,
    3. Shridhar V,
    4. Schildkraut JM,
    5. Armasu S,
    6. Hartmann LC,
    7. Fridley BL,
    8. Cunningham JM,
    9. Phelan CM,
    10. Sellers TA and
    11. Goode EL
    : Polymorphisms in TCEAL7 and risk of epithelial ovarian cancer. Gynecol Oncol 114(2): 260-264, 2009. PMID: 19419758. DOI: 10.1016/j.ygyno.2009.03.038
    OpenUrlCrossRefPubMed
  45. ↵
    1. Wang J,
    2. Liu Y,
    3. Ji R,
    4. Gu Q,
    5. Zhao X,
    6. Liu Y and
    7. Sun B
    : Prognostic value of the X-linked inhibitor of apoptosis protein for invasive ductal breast cancer with triple-negative phenotype. Hum Pathol 41(8): 1186-1195, 2010. PMID: 20381828. DOI: 10.1016/j.humpath.2010.01.013
    OpenUrlCrossRefPubMed
    1. Zhou S,
    2. Ye W,
    3. Shao Q,
    4. Qi Y,
    5. Zhang M and
    6. Liang J
    : Prognostic significance of XIAP and NF-κB expression in esophageal carcinoma with postoperative radiotherapy. World J Surg Oncol 11: 288, 2013. PMID: 24188482. DOI: 10.1186/1477-7819-11-288
    OpenUrlCrossRefPubMed
    1. Huang X,
    2. Wang XN,
    3. Yuan XD,
    4. Wu WY,
    5. Lobie PE and
    6. Wu Z
    : XIAP facilitates breast and colon carcinoma growth via promotion of p62 depletion through ubiquitination-dependent proteasomal degradation. Oncogene 38(9): 1448-1460, 2019. PMID: 30275562. DOI: 10.1038/s41388-018-0513-8
    OpenUrlCrossRefPubMed
    1. Yoo JK,
    2. Lee JM,
    3. Kang SH,
    4. Jeon SH,
    5. Kim CM,
    6. Oh SH,
    7. Kim CH,
    8. Kim NK and
    9. Kim JK
    : The novel microRNA hsa-miR-CHA1 regulates cell proliferation and apoptosis in human lung cancer by targeting XIAP. Lung Cancer 132: 99-106, 2019. PMID: 31097102. DOI: 10.1016/j.lungcan.2018.04.011
    OpenUrlCrossRefPubMed
  46. ↵
    1. Tu H and
    2. Costa M
    : XIAP’s profile in human cancer. Biomolecules 10(11): 1493, 2020. PMID: 33138314. DOI: 10.3390/biom10111493
    OpenUrlCrossRefPubMed
  47. ↵
    1. Peng H,
    2. Wang LG,
    3. Wang XZ and
    4. Liu AJ
    : The correlation between XIAP gene polymorphisms and esophageal squamous cell carcinoma susceptibility and prognosis in a Chinese population. Pathol Res Pract 213(12): 1482-1488, 2017. PMID: 29037837. DOI: 10.1016/j.prp.2017.10.008
    OpenUrlCrossRefPubMed
  48. ↵
    1. Zuo XY,
    2. Feng QS,
    3. Sun J,
    4. Wei PP,
    5. Chin YM,
    6. Guo YM,
    7. Xia YF,
    8. Li B,
    9. Xia XJ,
    10. Jia WH,
    11. Liu JJ,
    12. Khoo AS,
    13. Mushiroda T,
    14. Ng CC,
    15. Su WH,
    16. Zeng YX and
    17. Bei JX
    : X-chromosome association study reveals genetic susceptibility loci of nasopharyngeal carcinoma. Biol Sex Differ 10(1): 13, 2019. PMID: 30909962. DOI: 10.1186/s13293-019-0227-9
    OpenUrlCrossRefPubMed
  49. ↵
    1. Tse KP,
    2. Su WH,
    3. Chang KP,
    4. Tsang NM,
    5. Yu CJ,
    6. Tang P,
    7. See LC,
    8. Hsueh C,
    9. Yang ML,
    10. Hao SP,
    11. Li HY,
    12. Wang MH,
    13. Liao LP,
    14. Chen LC,
    15. Lin SR,
    16. Jorgensen TJ,
    17. Chang YS and
    18. Shugart YY
    : Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. Am J Hum Genet 85(2): 194-203, 2009. PMID: 19664746. DOI: 10.1016/j.ajhg.2009.07.007
    OpenUrlCrossRefPubMed
  50. ↵
    1. Chin YM,
    2. Mushiroda T,
    3. Takahashi A,
    4. Kubo M,
    5. Krishnan G,
    6. Yap LF,
    7. Teo SH,
    8. Lim PV,
    9. Yap YY,
    10. Pua KC,
    11. Kamatani N,
    12. Nakamura Y,
    13. Sam CK,
    14. Khoo AS, Malaysian NPC Study Group and Ng CC
    : HLA-A SNPs and amino acid variants are associated with nasopharyngeal carcinoma in Malaysian Chinese. Int J Cancer 136(3): 678-687, 2015. PMID: 24947555. DOI: 10.1002/ijc.29035
    OpenUrlCrossRefPubMed
  51. ↵
    1. Ng CC,
    2. Yew PY,
    3. Puah SM,
    4. Krishnan G,
    5. Yap LF,
    6. Teo SH,
    7. Lim PV,
    8. Govindaraju S,
    9. Ratnavelu K,
    10. Sam CK,
    11. Takahashi A,
    12. Kubo M,
    13. Kamatani N,
    14. Nakamura Y and
    15. Mushiroda T
    : A genome-wide association study identifies ITGA9 conferring risk of nasopharyngeal carcinoma. J Hum Genet 54(7): 392-397, 2009. PMID: 19478819. DOI: 10.1038/jhg.2009.49
    OpenUrlCrossRefPubMed
  52. ↵
    1. Taran LD
    : Factor IX of the blood coagulation system: a review. Biochemistry (Mosc) 62(7): 685-693, 1997. PMID: 9331959.
    OpenUrlPubMed
  53. ↵
    1. Bublik DR,
    2. Bursać S,
    3. Sheffer M,
    4. Oršolić I,
    5. Shalit T,
    6. Tarcic O,
    7. Kotler E,
    8. Mouhadeb O,
    9. Hoffman Y,
    10. Fuchs G,
    11. Levin Y,
    12. Volarević S and
    13. Oren M
    : Regulatory module involving FGF13, miR-504, and p53 regulates ribosomal biogenesis and supports cancer cell survival. Proc Natl Acad Sci U S A 114(4): E496-E505, 2017. PMID: 27994142. DOI: 10.1073/pnas.1614876114
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Gaudet MM,
    2. Kuchenbaecker KB,
    3. Vijai J,
    4. Klein RJ,
    5. Kirchhoff T,
    6. McGuffog L,
    7. Barrowdale D,
    8. Dunning AM,
    9. Lee A,
    10. Dennis J,
    11. Healey S,
    12. Dicks E,
    13. Soucy P,
    14. Sinilnikova OM,
    15. Pankratz VS,
    16. Wang X,
    17. Eldridge RC,
    18. Tessier DC,
    19. Vincent D,
    20. Bacot F,
    21. Hogervorst FB,
    22. Peock S,
    23. Stoppa-Lyonnet D, KConFab Investigators.,
    24. Peterlongo P,
    25. Schmutzler RK,
    26. Nathanson KL,
    27. Piedmonte M,
    28. Singer CF,
    29. Thomassen M, Ontario Cancer Genetics Network,
    30. Hansen Tv,
    31. Neuhausen SL,
    32. Blanco I,
    33. Greene MH,
    34. Garber J,
    35. Weitzel JN,
    36. Andrulis IL,
    37. Goldgar DE,
    38. D’Andrea E,
    39. Caldes T,
    40. Nevanlinna H,
    41. Osorio A,
    42. van Rensburg EJ,
    43. Arason A,
    44. Rennert G,
    45. van den Ouweland AM,
    46. van der Hout AH,
    47. Kets CM,
    48. Aalfs CM,
    49. Wijnen JT,
    50. Ausems MG, HEBON, EMBRACE,
    51. Frost D,
    52. Ellis S,
    53. Fineberg E,
    54. Platte R,
    55. Evans DG,
    56. Jacobs C,
    57. Adlard J,
    58. Tischkowitz M,
    59. Porteous ME,
    60. Damiola F, GEMO Study Collaborators,
    61. Golmard L,
    62. Barjhoux L,
    63. Longy M,
    64. Belotti M,
    65. Ferrer SF,
    66. Mazoyer S,
    67. Spurdle AB,
    68. Manoukian S,
    69. Barile M,
    70. Genuardi M,
    71. Arnold N,
    72. Meindl A,
    73. Sutter C,
    74. Wappenschmidt B,
    75. Domchek SM,
    76. Pfeiler G,
    77. Friedman E,
    78. Jensen UB,
    79. Robson M,
    80. Shah S,
    81. Lazaro C,
    82. Mai PL,
    83. Benitez J,
    84. Southey MC,
    85. Schmidt MK,
    86. Fasching PA,
    87. Peto J,
    88. Humphreys MK,
    89. Wang Q,
    90. Michailidou K,
    91. Sawyer EJ,
    92. Burwinkel B,
    93. Guénel P,
    94. Bojesen SE,
    95. Milne RL,
    96. Brenner H,
    97. Lochmann M,
    98. GENICA Network, Aittomäki K,
    99. Dörk T,
    100. Margolin S,
    101. Mannermaa A,
    102. Lambrechts D,
    103. Chang-Claude J,
    104. Radice P,
    105. Giles GG,
    106. Haiman CA,
    107. Winqvist R,
    108. Devillee P,
    109. García-Closas M,
    110. Schoof N,
    111. Hooning MJ,
    112. Cox A,
    113. Pharoah PD,
    114. Jakubowska A,
    115. Orr N,
    116. González-Neira A,
    117. Pita G,
    118. Alonso MR,
    119. Hall P,
    120. Couch FJ,
    121. Simard J,
    122. Altshuler D,
    123. Easton DF,
    124. Chenevix-Trench G,
    125. Antoniou AC and
    126. Offit K
    : Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet 9(3): e1003173, 2013. PMID: 23544012. DOI: 10.1371/journal.pgen.1003173
    OpenUrlCrossRefPubMed
  55. ↵
    1. Szylberg Ł,
    2. Karbownik D and
    3. Marszałek A
    : The role of FOXP3 in human cancers. Anticancer Res 36(8): 3789-3794, 2016. PMID: 27466478.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Raskin L,
    2. Rennert G and
    3. Gruber SB
    : FOXP3 germline polymorphisms are not associated with risk of breast cancer. Cancer Genet Cytogenet 190(1): 40-42, 2009. PMID: 19264232. DOI: 10.1016/j.cancergencyto.2008.12.005
    OpenUrlCrossRefPubMed
  57. ↵
    1. Chen Y,
    2. Zhang H,
    3. Liao W,
    4. Zhou J,
    5. He G,
    6. Xie X,
    7. Fei R,
    8. Qin L,
    9. Wei L and
    10. Chen H
    : FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. J Exp Clin Cancer Res 32: 39, 2013. PMID: 23759077. DOI: 10.1186/1756-9966-32-39
    OpenUrlCrossRefPubMed
    1. He YQ,
    2. Bo Q,
    3. Yong W,
    4. Qiu ZX,
    5. Li YL and
    6. Li WM
    : FoxP3 genetic variants and risk of non-small cell lung cancer in the Chinese Han population. Gene 531(2): 422-425, 2013. PMID: 24035934. DOI: 10.1016/j.gene.2013.08.066
    OpenUrlCrossRefPubMed
  58. ↵
    1. Zheng J,
    2. Deng J,
    3. Jiang L,
    4. Yang L,
    5. You Y,
    6. Hu M,
    7. Li N,
    8. Wu H,
    9. Li W,
    10. Li H,
    11. Lu J and
    12. Zhou Y
    : Heterozygous genetic variations of FOXP3 in Xp11.23 elevate breast cancer risk in Chinese population via skewed X-chromosome inactivation. Hum Mutat 34(4): 619-628, 2013. PMID: 23378296. DOI: 10.1002/humu.22284
    OpenUrlCrossRefPubMed
  59. ↵
    1. Jahan P,
    2. Ramachander VR,
    3. Maruthi G,
    4. Nalini S,
    5. Latha KP and
    6. Murthy TS
    : Foxp3 promoter polymorphism (rs3761548) in breast cancer progression: a study from India. Tumour Biol 35(4): 3785-3791, 2014. PMID: 24338714. DOI: 10.1007/s13277-013-1501-9
    OpenUrlCrossRefPubMed
  60. ↵
    1. Jiang LL and
    2. Ruan LW
    : Association between FOXP3 promoter polymorphisms and cancer risk: A meta-analysis. Oncol Lett 8(6): 2795-2799, 2014. PMID: 25364468. DOI: 10.3892/ol.2014.2585
    OpenUrlCrossRefPubMed
  61. ↵
    1. Chen L,
    2. Yu Q,
    3. Liu B and
    4. Zhu L
    : Association of FoxP3 rs3761548 polymorphism with susceptibility to colorectal cancer in the Chinese population. Med Oncol 31(12): 374, 2014. PMID: 25416053. DOI: 10.1007/s12032-014-0374-0
    OpenUrlCrossRefPubMed
  62. ↵
    1. Jiang W,
    2. Zheng L,
    3. Xu L,
    4. Zhang Y,
    5. Liu X,
    6. Hu L and
    7. Wang X
    : Association between FOXP3 gene polymorphisms and risk of differentiated thyroid cancer in Chinese Han population. J Clin Lab Anal 31(5): e22104, 2017. PMID: 27892628. DOI: 10.1002/jcla.22104
    OpenUrlCrossRefPubMed
  63. ↵
    1. You D,
    2. Wang Y,
    3. Zhang Y,
    4. Li Q,
    5. Yu X,
    6. Yuan M,
    7. Lan Z,
    8. Zeng X,
    9. Zhou B,
    10. Song Y,
    11. Su M,
    12. Zhang L and
    13. Xi M
    : Association of Foxp3 promoter polymorphisms with susceptibility to endometrial cancer in the Chinese Han women. Medicine (Baltimore) 97(18): e0582, 2018. PMID: 29718856. DOI: 10.1097/MD.0000000000010582
    OpenUrlCrossRefPubMed
  64. ↵
    1. Gao L,
    2. Li K,
    3. Li F,
    4. Li H,
    5. Liu L,
    6. Wang L,
    7. Zhang Z,
    8. Gao T and
    9. Liu Y
    : Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients. J Dermatol Sci 57(1): 51-56, 2010. PMID: 19880293. DOI: 10.1016/j.jdermsci.2009.09.010
    OpenUrlCrossRefPubMed
  65. ↵
    1. Wang Y,
    2. Liao H,
    3. Zheng HC,
    4. Li L,
    5. Jia L,
    6. Zhang Z and
    7. Zheng W
    : Effect of luteinizing hormone-induced prohibitin and matrix metalloproteinases on ovarian epithelial tumor cell proliferation. Am J Cancer Res 5(1): 114-124, 2014. PMID: 25628924.
    OpenUrlPubMed
  66. ↵
    1. Fazelzadeh Haghighi M,
    2. Ali Ghayumi M,
    3. Behzadnia F and
    4. Erfani N
    : Investigation of FOXP3 genetic variations at positions -2383 C/T and IVS9+459 T/C in southern Iranian patients with lung carcinoma. Iran J Basic Med Sci 18(5): 465-471, 2015. PMID: 26124932.
    OpenUrlPubMed
  67. ↵
    1. Kwon TK,
    2. Chung EJ,
    3. Lee N,
    4. Roh EY and
    5. Song EY
    : Associations of FoxP3 gene polymorphisms with severe recurrent respiratory papillomatosis in Korean patients. J Otolaryngol Head Neck Surg 46(1): 21, 2017. PMID: 28298239. DOI: 10.1186/s40463-017-0197-z
    OpenUrlCrossRefPubMed
  68. ↵
    1. Pang YY,
    2. Li JD,
    3. Gao L,
    4. Yang X,
    5. Dang YW,
    6. Lai ZF,
    7. Liu LM,
    8. Yang J,
    9. Wu HY,
    10. He RQ,
    11. Huang ZG,
    12. Xiong DD,
    13. Yang LH,
    14. Shi L,
    15. Mo WJ,
    16. Tang D,
    17. Lu HP and
    18. Chen G
    : The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissues. Cancer Med 9(21): 8004-8019, 2020. PMID: 32931665. DOI: 10.1002/cam4.3434
    OpenUrlCrossRefPubMed
  69. ↵
    1. Sjöberg RL,
    2. Wu WY,
    3. Dahlin AM,
    4. Tsavachidis S,
    5. Gliogene Group., Bondy ML and
    6. Melin B
    : Role of monoamine-oxidase-A-gene variation in the development of glioblastoma in males: a case control study. J Neurooncol 145(2): 287-294, 2019. PMID: 31556016. DOI: 10.1007/s11060-019-03294-w
    OpenUrlCrossRefPubMed
  70. ↵
    1. Grisanzio C,
    2. Werner L,
    3. Takeda D,
    4. Awoyemi BC,
    5. Pomerantz MM,
    6. Yamada H,
    7. Sooriakumaran P,
    8. Robinson BD,
    9. Leung R,
    10. Schinzel AC,
    11. Mills I,
    12. Ross-Adams H,
    13. Neal DE,
    14. Kido M,
    15. Yamamoto T,
    16. Petrozziello G,
    17. Stack EC,
    18. Lis R,
    19. Kantoff PW,
    20. Loda M,
    21. Sartor O,
    22. Egawa S,
    23. Tewari AK,
    24. Hahn WC and
    25. Freedman ML
    : Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A 109(28): 11252-11257, 2012. PMID: 22730461. DOI: 10.1073/pnas.1200853109
    OpenUrlAbstract/FREE Full Text
  71. ↵
    1. Li W and
    2. Gu M
    : NUDT11 rs5945572 polymorphism and prostate cancer risk: a meta-analysis. Int J Clin Exp Med 8(3): 3474-3481, 2015. PMID: 26064238.
    OpenUrlPubMed
  72. ↵
    1. Cremers RG,
    2. Galesloot TE,
    3. Aben KK,
    4. van Oort IM,
    5. Vasen HF,
    6. Vermeulen SH and
    7. Kiemeney LA
    : Known susceptibility SNPs for sporadic prostate cancer show a similar association with “hereditary” prostate cancer. Prostate 75(5): 474-483, 2015. PMID: 25560306. DOI: 10.1002/pros.22933
    OpenUrlCrossRefPubMed
  73. ↵
    1. Chang BL,
    2. Spangler E,
    3. Gallagher S,
    4. Haiman CA,
    5. Henderson B,
    6. Isaacs W,
    7. Benford ML,
    8. Kidd LR,
    9. Cooney K,
    10. Strom S,
    11. Ingles SA,
    12. Stern MC,
    13. Corral R,
    14. Joshi AD,
    15. Xu J,
    16. Giri VN,
    17. Rybicki B,
    18. Neslund-Dudas C,
    19. Kibel AS,
    20. Thompson IM,
    21. Leach RJ,
    22. Ostrander EA,
    23. Stanford JL,
    24. Witte J,
    25. Casey G,
    26. Eeles R,
    27. Hsing AW,
    28. Chanock S,
    29. Hu JJ,
    30. John EM,
    31. Park J,
    32. Stefflova K,
    33. Zeigler-Johnson C and
    34. Rebbeck TR
    : Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev 20(1): 23-32, 2011. PMID: 21071540. DOI: 10.1158/1055-9965.EPI-10-0698
    OpenUrlAbstract/FREE Full Text
    1. Agalliu I,
    2. Wang Z,
    3. Wang T,
    4. Dunn A,
    5. Parikh H,
    6. Myers T,
    7. Burk RD and
    8. Amundadottir L
    : Characterization of SNPs associated with prostate cancer in men of Ashkenazic descent from the set of GWAS identified SNPs: impact of cancer family history and cumulative SNP risk prediction. PLoS One 8(4): e60083, 2013. PMID: 23573233. DOI: 10.1371/journal.pone.0060083
    OpenUrlCrossRefPubMed
  74. ↵
    1. Tao S,
    2. Wang Z,
    3. Feng J,
    4. Hsu FC,
    5. Jin G,
    6. Kim ST,
    7. Zhang Z,
    8. Gronberg H,
    9. Zheng LS,
    10. Isaacs WB,
    11. Xu J and
    12. Sun J
    : A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants. Carcinogenesis 33(3): 598-603, 2012. PMID: 22219177. DOI: 10.1093/carcin/bgr316
    OpenUrlCrossRefPubMed
  75. ↵
    1. Jackson HW,
    2. Defamie V,
    3. Waterhouse P and
    4. Khokha R
    : TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer 17(1): 38-53, 2017. PMID: 27932800. DOI: 10.1038/nrc.2016.115
    OpenUrlCrossRefPubMed
  76. ↵
    1. Chang WS,
    2. Liu LC,
    3. Hsiao CL,
    4. Su CH,
    5. Wang HC,
    6. Ji HX,
    7. Tsai CW,
    8. Maa MC and
    9. Bau DT
    : The contributions of the tissue inhibitor of metalloproteinase-1 genotypes to triple negative breast cancer risk. Biomedicine (Taipei) 6(1): 4, 2016. PMID: 26872812. DOI: 10.7603/s40681-016-0004-6
    OpenUrlCrossRefPubMed
  77. ↵
    1. Lai CY,
    2. Chang WS,
    3. Hsieh YH,
    4. Hsu CM,
    5. Tsai CW,
    6. Chen AC,
    7. Wang CH and
    8. Bau DT
    : Association of tissue inhibitor of metalloproteinase-1 genotypes with lung cancer risk in Taiwan. Anticancer Res 36(1): 155-160, 2016. PMID: 26722039.
    OpenUrlAbstract/FREE Full Text
  78. ↵
    1. Li J,
    2. Liu Y and
    3. Yin Y
    : Inhibitory effects of Arhgap6 on cervical carcinoma cells. Tumour Biol 37(2): 1411-1425, 2016. PMID: 26628301. DOI: 10.1007/s13277-015-4502-z
    OpenUrlCrossRefPubMed
  79. ↵
    1. Wu Y,
    2. Xu M,
    3. He R,
    4. Xu K and
    5. Ma Y
    : ARHGAP6 regulates the proliferation, migration and invasion of lung cancer cells. Oncol Rep 41(4): 2281-2888, 2019. PMID: 30816546. DOI: 10.3892/or.2019.7031
    OpenUrlCrossRefPubMed
  80. ↵
    1. Guo F,
    2. Liu Y,
    3. Huang J,
    4. Li Y,
    5. Zhou G,
    6. Wang D,
    7. Li Y,
    8. Wang J,
    9. Xie P and
    10. Li G
    : Identification of Rho GTPase activating protein 6 isoform 1 variant as a new molecular marker in human colorectal tumors. Pathol Oncol Res 16(3): 319-326, 2010. PMID: 19960375. DOI: 10.1007/s12253-009-9226-1
    OpenUrlCrossRefPubMed
  81. ↵
    1. Jones L,
    2. Naidoo M,
    3. Machado LR and
    4. Anthony K
    : The Duchenne muscular dystrophy gene and cancer. Cell Oncol (Dordr) 44(1): 19-32, 2021. PMID: 33188621. DOI: 10.1007/s13402-020-00572-y
    OpenUrlCrossRefPubMed
  82. ↵
    1. Dunlop MG,
    2. Dobbins SE,
    3. Farrington SM,
    4. Jones AM,
    5. Palles C,
    6. Whiffin N,
    7. Tenesa A,
    8. Spain S,
    9. Broderick P,
    10. Ooi LY,
    11. Domingo E,
    12. Smillie C,
    13. Henrion M,
    14. Frampton M,
    15. Martin L,
    16. Grimes G,
    17. Gorman M,
    18. Semple C,
    19. Ma YP,
    20. Barclay E,
    21. Prendergast J,
    22. Cazier JB,
    23. Olver B,
    24. Penegar S,
    25. Lubbe S,
    26. Chander I,
    27. Carvajal-Carmona LG,
    28. Ballereau S,
    29. Lloyd A,
    30. Vijayakrishnan J,
    31. Zgaga L,
    32. Rudan I,
    33. Theodoratou E, Colorectal Tumour Gene Identification (CORGI) Consortium,
    34. Starr JM,
    35. Deary I,
    36. Kirac I,
    37. Kovacević D,
    38. Aaltonen LA,
    39. Renkonen-Sinisalo L,
    40. Mecklin JP,
    41. Matsuda K,
    42. Nakamura Y,
    43. Okada Y,
    44. Gallinger S,
    45. Duggan DJ,
    46. Conti D,
    47. Newcomb P,
    48. Hopper J,
    49. Jenkins MA,
    50. Schumacher F,
    51. Casey G,
    52. Easton D,
    53. Shah M,
    54. Pharoah P,
    55. Lindblom A,
    56. Liu T, Swedish Low-Risk Colorectal Cancer Study Group,
    57. Smith CG,
    58. West H,
    59. Cheadle JP, COIN Collaborative Group,
    60. Midgley R,
    61. Kerr DJ,
    62. Campbell H,
    63. Tomlinson IP and
    64. Houlston RS
    : Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet 44(7): 770-776, 2012. PMID: 22634755. DOI: 10.1038/ng.2293
    OpenUrlCrossRefPubMed
  83. ↵
    1. Yuan J,
    2. Chen L,
    3. Xiao J,
    4. Qi XK,
    5. Zhang J,
    6. Li X,
    7. Wang Z,
    8. Lian YF,
    9. Xiang T,
    10. Zhang Y,
    11. Chen MY,
    12. Bei JX,
    13. Zeng YX and
    14. Feng L
    : SHROOM2 inhibits tumor metastasis through RhoA-ROCK pathway-dependent and -independent mechanisms in nasopharyngeal carcinoma. Cell Death Dis 10(2): 58, 2019. PMID: 30683844. DOI: 10.1038/s41419-019-1325-7
    OpenUrlCrossRefPubMed
  84. ↵
    1. Eeles RA,
    2. Olama AA,
    3. Benlloch S,
    4. Saunders EJ,
    5. Leongamornlert DA,
    6. Tymrakiewicz M,
    7. Ghoussaini M,
    8. Luccarini C,
    9. Dennis J,
    10. Jugurnauth-Little S,
    11. Dadaev T,
    12. Neal DE,
    13. Hamdy FC,
    14. Donovan JL,
    15. Muir K,
    16. Giles GG,
    17. Severi G,
    18. Wiklund F,
    19. Gronberg H,
    20. Haiman CA,
    21. Schumacher F,
    22. Henderson BE,
    23. Le Marchand L,
    24. Lindstrom S,
    25. Kraft P,
    26. Hunter DJ,
    27. Gapstur S,
    28. Chanock SJ,
    29. Berndt SI,
    30. Albanes D,
    31. Andriole G,
    32. Schleutker J,
    33. Weischer M,
    34. Canzian F,
    35. Riboli E,
    36. Key TJ,
    37. Travis RC,
    38. Campa D,
    39. Ingles SA,
    40. John EM,
    41. Hayes RB,
    42. Pharoah PD,
    43. Pashayan N,
    44. Khaw KT,
    45. Stanford JL,
    46. Ostrander EA,
    47. Signorello LB,
    48. Thibodeau SN,
    49. Schaid D,
    50. Maier C,
    51. Vogel W,
    52. Kibel AS,
    53. Cybulski C,
    54. Lubinski J,
    55. Cannon-Albright L,
    56. Brenner H,
    57. Park JY,
    58. Kaneva R,
    59. Batra J,
    60. Spurdle AB,
    61. Clements JA,
    62. Teixeira MR,
    63. Dicks E,
    64. Lee A,
    65. Dunning AM,
    66. Baynes C,
    67. Conroy D,
    68. Maranian MJ,
    69. Ahmed S,
    70. Govindasami K,
    71. Guy M,
    72. Wilkinson RA,
    73. Sawyer EJ,
    74. Morgan A,
    75. Dearnaley DP,
    76. Horwich A,
    77. Huddart RA,
    78. Khoo VS,
    79. Parker CC,
    80. Van As NJ,
    81. Woodhouse CJ,
    82. Thompson A,
    83. Dudderidge T,
    84. Ogden C,
    85. Cooper CS,
    86. Lophatananon A,
    87. Cox A,
    88. Southey MC,
    89. Hopper JL,
    90. English DR,
    91. Aly M,
    92. Adolfsson J,
    93. Xu J,
    94. Zheng SL,
    95. Yeager M,
    96. Kaaks R,
    97. Diver WR,
    98. Gaudet MM,
    99. Stern MC,
    100. Corral R,
    101. Joshi AD,
    102. Shahabi A,
    103. Wahlfors T,
    104. Tammela TL,
    105. Auvinen A,
    106. Virtamo J,
    107. Klarskov P,
    108. Nordestgaard BG,
    109. Røder MA,
    110. Nielsen SF,
    111. Bojesen SE,
    112. Siddiq A,
    113. Fitzgerald LM,
    114. Kolb S,
    115. Kwon EM,
    116. Karyadi DM,
    117. Blot WJ,
    118. Zheng W,
    119. Cai Q,
    120. McDonnell SK,
    121. Rinckleb AE,
    122. Drake B,
    123. Colditz G,
    124. Wokolorczyk D,
    125. Stephenson RA,
    126. Teerlink C,
    127. Muller H,
    128. Rothenbacher D,
    129. Sellers TA,
    130. Lin HY,
    131. Slavov C,
    132. Mitev V,
    133. Lose F,
    134. Srinivasan S,
    135. Maia S,
    136. Paulo P,
    137. Lange E,
    138. Cooney KA,
    139. Antoniou AC,
    140. Vincent D,
    141. Bacot F,
    142. Tessier DC, COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative, Australian Prostate Cancer Bioresource, UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons’ Section of Oncology, UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators, PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium,
    143. Kote-Jarai Z and
    144. Easton DF
    : Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 45(4): 385-91, 391e1-2, 2013. PMID: 23535732. DOI: 10.1038/ng.2560
    OpenUrlCrossRefPubMed
  85. ↵
    1. Al-Humairi RMA,
    2. Al-Musawi MT and
    3. Ad’hiah AH
    : Serum level and single-nucleotide polymorphisms of toll-like receptor-7 among urinary bladder cancer Iraqi patients. Egypt J Med Hum Genet 20: 11, 2019. DOI: 10.1186/s43042-019-0015-4
    OpenUrlCrossRef
  86. ↵
    1. Monroy CM,
    2. Cortes AC,
    3. Lopez MS,
    4. D’Amelio AM Jr.,
    5. Etzel CJ,
    6. Younes A,
    7. Strom SS and
    8. El-Zein RA
    : Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes. Mol Carcinog 50(1): 36-46, 2011. PMID: 21061265. DOI: 10.1002/mc.20688
    OpenUrlCrossRefPubMed
  87. ↵
    1. Kawasaki A,
    2. Furukawa H,
    3. Kondo Y,
    4. Ito S,
    5. Hayashi T,
    6. Kusaoi M,
    7. Matsumoto I,
    8. Tohma S,
    9. Takasaki Y,
    10. Hashimoto H,
    11. Sumida T and
    12. Tsuchiya N
    : TLR7 single-nucleotide polymorphisms in the 3’ untranslated region and intron 2 independently contribute to systemic lupus erythematosus in Japanese women: a case-control association study. Arthritis Res Ther 13(2): R41, 2011. PMID: 21396113. DOI: 10.1186/ar3277
    OpenUrlCrossRefPubMed
  88. ↵
    1. Raafat II,
    2. El Guindy N,
    3. Shahin RMH,
    4. Samy LA and
    5. El Refai RM
    : Toll-like receptor 7 gene single nucleotide polymorphisms and the risk for systemic lupus erythematosus: a case-control study. Z Rheumatol 77(5): 416-420, 2018. PMID: 28243744. DOI: 10.1007/s00393-017-0283-7
    OpenUrlCrossRefPubMed
  89. ↵
    1. Zhu Y,
    2. Shao X,
    3. Wang X,
    4. Liu L and
    5. Liang H
    : Sex disparities in cancer. Cancer Lett 466: 35-38, 2019. PMID: 31541696. DOI: 10.1016/j.canlet.2019.08.017
    OpenUrlCrossRefPubMed
  90. ↵
    1. Dorak MT and
    2. Karpuzoglu E
    : Gender differences in cancer susceptibility: an inadequately addressed issue. Front Genet 3: 268, 2012. PMID: 23226157. DOI: 10.3389/fgene.2012.00268
    OpenUrlCrossRefPubMed
  91. ↵
    1. Clocchiatti A,
    2. Cora E,
    3. Zhang Y and
    4. Dotto GP
    : Sexual dimorphism in cancer. Nat Rev Cancer 16(5): 330-339, 2016. PMID: 27079803. DOI: 10.1038/nrc.2016.30
    OpenUrlCrossRefPubMed
  92. ↵
    1. Zheng D,
    2. Williams C,
    3. Vold JA,
    4. Nguyen JH,
    5. Harnois DM,
    6. Bagaria SP,
    7. McLaughlin SA and
    8. Li Z
    : Regulation of sex hormone receptors in sexual dimorphism of human cancers. Cancer Lett 438: 24-31, 2018. PMID: 30223066. DOI: 10.1016/j.canlet.2018.09.001
    OpenUrlCrossRefPubMed
  93. ↵
    1. Zheng G,
    2. Joo J,
    3. Zhang C and
    4. Geller NL
    : Testing association for markers on the X chromosome. Genet Epidemiol 31(8): 834-843, 2007. PMID: 17549761. DOI: 10.1002/gepi.20244
    OpenUrlCrossRefPubMed
  94. ↵
    1. Clayton D
    : Testing for association on the X chromosome. Biostatistics 9(4): 593-600, 2008. PMID: 18441336. DOI: 10.1093/biostatistics/kxn007
    OpenUrlCrossRefPubMed
  95. ↵
    1. Li BH,
    2. Yu WY and
    3. Zhou JY
    : A statistical measure for the skewness of X chromosome inactivation for quantitative traits and its application to the MCTFR data. BMC Genom Data 22(1): 24, 2021. PMID: 34215184. DOI: 10.1186/s12863-021-00978-z
    OpenUrlCrossRefPubMed
  96. ↵
    1. Backenroth D and
    2. Carmi S
    : A test for deviations from expected genotype frequencies on the X chromosome for sex-biased admixed populations. Heredity (Edinb) 123(4): 470-478, 2019. PMID: 31101879. DOI: 10.1038/s41437-019-0233-z
    OpenUrlCrossRefPubMed
  97. ↵
    1. Gao F,
    2. Chang D,
    3. Biddanda A,
    4. Ma L,
    5. Guo Y,
    6. Zhou Z and
    7. Keinan A
    : XWAS: a software toolset for genetic data analysis and association studies of the X chromosome. J Hered 106(5): 666-671, 2015. PMID: 26268243. DOI: 10.1093/jhered/esv059
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (5)
Anticancer Research
Vol. 42, Issue 5
May 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Implication of X-Linked Genetic Polymorphisms in Susceptibility and Sexual Dimorphism of Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The Implication of X-Linked Genetic Polymorphisms in Susceptibility and Sexual Dimorphism of Cancer
CHAROULA ACHILLA, THEODOSIOS PAPAVRAMIDIS, LEFTERIS ANGELIS, ANTHOULA CHATZIKYRIAKIDOU
Anticancer Research May 2022, 42 (5) 2261-2276; DOI: 10.21873/anticanres.15706

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
The Implication of X-Linked Genetic Polymorphisms in Susceptibility and Sexual Dimorphism of Cancer
CHAROULA ACHILLA, THEODOSIOS PAPAVRAMIDIS, LEFTERIS ANGELIS, ANTHOULA CHATZIKYRIAKIDOU
Anticancer Research May 2022, 42 (5) 2261-2276; DOI: 10.21873/anticanres.15706
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methodology
    • Germline Genetic Polymorphisms on the X-Chromosome Involved in Cancer
    • Genetic Polymorphisms of Genes Located in the PAR1
    • Genetic Polymorphisms in Genes With Very Low Probability of Escaping X-Chromosome Inactivation
    • Genetic Polymorphisms in Genes With a Low Probability of Escaping X-Chromosome Inactivation
    • Genetic Polymorphisms in Genes With a High Probability of Escaping X-Chromosome Inactivation
    • Interaction Between Genes Involved in Cancer Susceptibility
    • Sexual Dimorphism in Cancer
    • Statistical Analysis of X-Chromosome Genetic Association Studies
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Mobile and Wireless Technologies for Gastrointestinal Cancer Treatment
  • De Novo Testicular Cancers Arising After Renal Transplantation: A Narrative Review
  • Adjuvant Treatment for Resectable Pancreatic Cancer
Show more Review

Similar Articles

Keywords

  • X-Chromosome
  • X-linked
  • polymorphism
  • cancer
  • gender dimorphism
  • review
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire